Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of ...

Memantine is a non-acetyl cholinesterase inhibitor that helps in Alzheimer's disease therapy. The medicine was approved for sale in Europe in 2002 and the United States Food and Drug Administration ...

Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe AD as ...

June 22, 2010 — Forest Laboratories Inc and Merz Pharmaceuticals GmbH announced yesterday they have received approval from the US Food and Drug Administration of an extended-release formulation of ...

The Food and Drug Administration approved the German medication memantine today to help ease the severe symptoms of an estimated 1 million Americans who suffer from the late stages of Alzheimer's ...

This medication is available in the form of tablet to take by mouth. It is usually taken once or twice a day with or without food. Headaches can occur due to several causes but normal fluctuations of ...

Memantine is approved to treat moderate to severe Alzheimer's disease and other dementias. Evidence suggests that it might also be useful with bipolar disorder, depression, schizophrenia and much more ...